Aurobindo Pharma Limited Fundamental Analysis
Aurobindo Pharma Limited Fundamental Analysis
Aurobindo Pharma Limited (AUROPHARMA.NS) shows moderate financial fundamentals with a PE ratio of 25.43, profit margin of 10.41%, and ROE of 10.14%. The company generates $333.3B in annual revenue with N/A year-over-year growth of N/A.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 74.9/100 based on profitability, valuation, growth, and balance sheet metrics. The B grade reflects solid fundamentals with room for improvement in valuation or growth.
Fundamental Health Score
We analyze AUROPHARMA.NS's fundamental strength across five key dimensions:
Efficiency Score
WeakAUROPHARMA.NS struggles to generate sufficient returns from assets.
Valuation Score
WeakAUROPHARMA.NS trades at a premium to fair value.
Growth Score
ModerateAUROPHARMA.NS shows steady but slowing expansion.
Financial Health Score
ExcellentAUROPHARMA.NS maintains a strong and stable balance sheet.
Profitability Score
WeakAUROPHARMA.NS struggles to sustain strong margins.
Key Financial Metrics
Is AUROPHARMA.NS Expensive or Cheap?
P/E Ratio
AUROPHARMA.NS trades at 25.43 times earnings. This indicates a fair valuation.
PEG Ratio
When adjusting for growth, AUROPHARMA.NS's PEG of 28.69 indicates potential overvaluation.
Price to Book
The market values Aurobindo Pharma Limited at 2.35 times its book value. This may indicate undervaluation.
EV/EBITDA
Enterprise value stands at 12.56 times EBITDA. This signals the market has high growth expectations.
How Well Does AUROPHARMA.NS Make Money?
Net Profit Margin
For every $100 in sales, Aurobindo Pharma Limited keeps $10.41 as profit after all expenses.
Operating Margin
Core operations generate 21.63 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $10.14 in profit for every $100 of shareholder equity.
ROA
Aurobindo Pharma Limited generates $5.99 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Aurobindo Pharma Limited generates limited operating cash flow of $28.58B, signaling weaker underlying cash strength.
Free Cash Flow
Aurobindo Pharma Limited produces free cash flow of $15.08B, offering steady but limited capital for shareholder returns and expansion.
FCF Per Share
Each share generates $26.20 in free cash annually.
FCF Yield
AUROPHARMA.NS converts 1.72% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
25.43
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
28.69
vs 25 benchmark
P/B Ratio
Price to book value ratio
2.35
vs 25 benchmark
P/S Ratio
Price to sales ratio
2.62
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.21
vs 25 benchmark
Current Ratio
Current assets to current liabilities
1.81
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.10
vs 25 benchmark
ROA
Return on assets percentage
0.06
vs 25 benchmark
ROCE
Return on capital employed
0.18
vs 25 benchmark
How AUROPHARMA.NS Stacks Against Its Sector Peers
| Metric | AUROPHARMA.NS Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 25.43 | 33.92 | Better (Cheaper) |
| ROE | 10.14% | 393.00% | Weak |
| Net Margin | 10.41% | -41456.00% (disorted) | Strong |
| Debt/Equity | 0.21 | 0.80 | Strong (Low Leverage) |
| Current Ratio | 1.81 | 4.57 | Neutral |
| ROA | 5.99% | -293.00% (disorted) | Weak |
AUROPHARMA.NS outperforms its industry in 3 out of 6 key metrics, particularly excelling in Net Margin, but lagging in ROE.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Aurobindo Pharma Limited's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
N/A
Industry Style: Defensive, Growth, Innovation
EPS CAGR
N/A
Industry Style: Defensive, Growth, Innovation
FCF CAGR
N/A
Industry Style: Defensive, Growth, Innovation